Medicine & Life Sciences
Breast Neoplasms
100%
Triple Negative Breast Neoplasms
53%
human ERBB2 protein
33%
Neoplasms
32%
Circulating Tumor DNA
26%
Circulating Neoplastic Cells
26%
Drug Therapy
25%
Biomarkers
25%
Cell-Free Nucleic Acids
25%
Hormones
21%
Survival
20%
Paclitaxel
18%
Trastuzumab
17%
Recurrence
17%
Therapeutics
15%
Early Detection of Cancer
15%
Neoplasm Metastasis
12%
MLN 8237
12%
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
12%
Residual Neoplasm
11%
Progression-Free Survival
11%
Estrogen Receptors
11%
Ado-Trastuzumab Emtansine
11%
Neoadjuvant Therapy
10%
pembrolizumab
10%
Randomized Controlled Trials
9%
Aurora Kinase A
9%
Practice Guidelines
8%
niraparib
8%
Medical Oncology
8%
Lapatinib
8%
Fulvestrant
7%
Brain Neoplasms
7%
pertuzumab
7%
Oncolytic Virotherapy
7%
Measles virus
7%
Disease-Free Survival
7%
Adjuvant Chemotherapy
7%
Carboplatin
7%
Genes
7%
Tumor-Infiltrating Lymphocytes
7%
Mutation
6%
Liquid Biopsy
6%
Safety
6%
Methylation
6%
Clinical Trials
6%
Aromatase Inhibitors
6%
Drug Development
6%
Technology
6%
Estrogen Receptor Modulators
5%